NY-CLOUDREACH
28.1.2021 15:02:31 CET | Business Wire | Press release
Cloudreach , the leading independent multi-cloud services company, today announced the launch of Cloudreach DevOps as a Service. This new offering combines Cloudreach development and operations, making them available ‘as a Service’ via a simple and flexible subscription model. DevOps as a Service is the first of its kind in the market, and fundamentally changes how cloud IT services are consumed to make it easy for enterprises to adopt cloud native technologies and practices.
Dave Chapman, Head of Strategy and Professional Services at Cloudreach, said: “Cloudreach DevOps as a Service brings a DevOps and cloud engineering skill set to any enterprise, whether they are new to the cloud or far along their modernization journey. Companies that undergo cloud transformation are better able to adapt to disruption, explore and innovate faster. This service helps technology leaders get the right skills in place, at the right time, and scale up and down to suit their changing requirements.”
Cloud acceleration
DevOps is a set of practices that combines software development and IT operations, removing the barriers between these traditionally siloed teams. Under a DevOps model, development and operations teams work together across the entire software application life cycle, from development and test through deployment to operations.
More than a decade after the introduction of cloud computing, many enterprises still find themselves suffering from the symptoms of legacy IT and legacy partners. Cloudreach DevOps as a Service makes cloud outsourcing easy by providing flexible engineering squads as a monthly subscription service. The new offering is designed to help technology leaders accelerate their cloud initiatives, embrace true DevOps within their teams, and help their organizations become more cloud native.
Cloudreach DevOps as a Service provides a core DevOps team that can be augmented to perform architecture, platform development, data engineering, application UX and product management roles, all as a unified service. As business priorities or backlogs change, the flexible nature of the service means customers can swap out squad members and scale the team up and down as needed, within a single statement of work. The minimum squad size includes two resources and 80 hours per month, with a minimum contract commitment of three months.
Cloudreach squads have a radical focus on trend improvement and platform evolution. They can help launch new products, accelerate and scale business initiatives, facilitate stronger collaboration with digital teams, or support key applications and infrastructure.
James Dunn, Head of Cloud Platform Development at Cloudreach, said: “Over its 10-year history, Cloudreach has delivered some of the largest and most successful cloud engineering projects in the world. Now we are bringing Cloudreach's cloud native expertise to market in a flexible subscription model.”
- ENDS -
About Cloudreach
Cloudreach is a leading independent cloud services company. Our mission is to deliver the promise of cloud and drive extraordinary value for our customers. Cloudreach helps enterprises win competitive advantage through successful cloud transformation.
With more than 10 years of cloud native experience, we've built an unmatched depth and breadth of expertise in cloud technologies and their application to business. For more information about our services, visit cloudreach.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005535/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom